TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03349281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pevonedistat
Description: Administered each cycle on days 1, 3 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Administered each cycle on days 1, 3 and 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pevonedistat
Description: Administered each cycle on days 1, 3 and 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Administered each cycle on days 2, 9, 16 and 23.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Administered each cycle on days 2, 9, 16 and 23.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Administered each cycle on days 2, 9, 16 and 23.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Taken orally each cycle on days 2 through 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken orally each cycle on days 2 through 15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Taken orally each cycle on days 2 through 15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-asparaginase
Description: Administered via intramuscular injection (IM) each cycle on days 9 and 23.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: Administered via intramuscular injection (IM) each cycle on days 9 and 23.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-asparaginase
Description: Administered via intramuscular injection (IM) each cycle on days 9 and 23.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Administered via IV each cycle on day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered via IV each cycle on day 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Administered via IV each cycle on day 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.
Study: NCT01648478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: It is a hyperinsulinemic-euglycemic clamp.
Description: The hyperinsulinemic-euglycemic clamp includes three periods:~* A basal period (from T-30 to T0)~* The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~* The infusion of glucose at variable rate (so as to maintain euglycemia)
Study: NCT00566345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)
Description: Trivalent, non-adjuvanted vaccine; dose: 0.5 ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate buffered saline
Description: Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
Study: NCT04427878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsies of subcutaneous adipose tissue
Description: Two 4mm punch biopsies of subcutaneous abdominal or thight adipose tissue
Study: NCT02943642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-dmDT390-bisFv(UCHT1)
Description: anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-dmDT390-bisFv(UCHT1)
Description: anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
Study: NCT04458181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Peer Journaling (PPJ)
Description: PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve subjective wellbeing in recovery and reduce relapse. PPJ uses journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Good wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health.
Study: NCT02081118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
Study: NCT03349281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Administered via IT injection to CNS positive subjects on days 9, 16, and 23.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Administered via IT injection to CNS positive subjects on days 9, 16, and 23.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
Study: NCT03579628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AsiDNA
Description: All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue.
Study: NCT04097197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief educational intervention
Description: same as before
Study: NCT03969264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Carbohydrate or Tree Nut Food Snacks
Description: Snack consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carbohydrate or Tree Nut Food Snacks
Description: Snack consumption
Study: NCT02972333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 80mg oral each day
Description: All eligible patients will have access to AZD9291 regimen through the ASTRIS study as long as they continue to show clinical benefit.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be implemented according to investigator's clinical practice.Based on the guidelines provided for the interruption of ADZ9291 with brain radiation therapy, a 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.
Study: NCT02081118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for HM11260C
Study: NCT00931918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin IV solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablet
Study: NCT02694796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program after a balneotherapy
Description: workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
Study: NCT01781013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-supported care
Description: The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
Study: NCT01219777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
Study: NCT03690921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
Description: Undergo LET-IMPT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00586118

Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU

Intervention type: DRUG
Intervention: Propofol
Description: Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
Study: NCT03453203

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Osteopathic Manipulative Treatment Using Counterstrain
Description: Described in arm/group descriptions

Intervention type: OTHER
Group type: OTHER
Intervention: Osteopathic Manipulative Treatment Using Counterstrain
Description: Described in arm/group descriptions
Study: NCT02606383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapaconazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Study: NCT02003378

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker sensor set to MV
Description: Pacemaker sensor set to minute ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker sensor set to XL
Description: Pacemaker sensor set to accelerometer
Study: NCT03228277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmutinib
Description: Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
Study: NCT01753596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological Sodium Chloride solution (0,9%)
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological Sodium Chloride solution (0,9%)
Description: Placebo
Study: NCT02633566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plantar orthoses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plantar orthoses
Study: NCT02959177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT00443677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COPPEBVCAD vs BEACOPP vs ABVD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPPEBVCAD vs BEACOPP vs ABVD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPPEBVCAD vs BEACOPP vs ABVD
Study: NCT01327027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Arginine, ADH
Description: Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; Sterile Saline
Description: Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
Study: NCT03630692

Intervention type: DRUG
Intervention: observance of oral drug treatment
Description: Completion of questionnaires at 4 times during patient's oral route drug treatment
Study: NCT02921139

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Description: Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-Transcatheter arterial chemoembolization (re-TACE)
Description: Patients with HCC after incomplete TACE are randomized to further re-TACE.
Study: NCT02209727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-Sibrotuzumab
Description: 50 mg Sibrotuzumab conjugated with 131I
Study: NCT00781417

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 50,000 IU once a week for 12 weeks then every other week for 40 weeks
Study: NCT05331781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Transversus Abdominis Plane Block
Description: patient in the supine position, ultrasound will be used to identify the plane between the internal oblique and transversus abdominis muscle to inject 20 ml of local anesthetic for each side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: intrathecal 150 microgram morphine in a 0.5 ml volume will be added to bupivacaine as an adjuvant to spinal anesthesia
Study: NCT00781417

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT01274559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Description: 1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
Study: NCT02219776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide solution Plus Chlorhexidine Scrub
Description: Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - Chlorhexidine Scrub only
Description: Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
Study: NCT01359618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single dose, oral encapsulated tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo comparator
Description: Single dose, oral encapsulated tablet
Study: NCT03383952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICAR19 CAR-T cells
Description: T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
Study: NCT01190111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-7
Description: 20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
Study: NCT04405622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus gemcitabine
Description: Subjects receive gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21 days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) maintenance. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
Study: NCT03309826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure
Description: Auto-PAP titration followed by fixed PAP treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Dilator Strip
Description: Nightly use of nasal dilator strip
Study: NCT03376217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPTp delivered by HSAs
Description: Pregnant women will have the option to receive IPTp-SP from Health surveillance assistants (HSAs). SP is recommended in Malawi for prevention of malaria during pregnancy, but currently it is only available at antenatal clinics.
Study: NCT04373798

Intervention type: DIAGNOSTIC_TEST
Intervention: C-reactive protein
Description: Measurement of CRP value from blood sample taken at covid19 check point (baseline).
Study: NCT00803205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to ataluren will be provided.
Study: NCT01944826

Intervention type: OTHER
Intervention: Registry of patients with Tako-Tsubo cardiomyopathy
Study: NCT04302480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Worksheets for ASP
Description: The ASP intervention will cover the harms and misleading marketing strategies of ASPs and other related information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Worksheets for SSB
Description: The SSB intervention will cover the general information on SSBs, such as the sugar content of SSBs, nutrition labels and the harms of SSBs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-messages for ASP
Description: In the subsequent month after the main intervention, students in the ASP group will receive 4-6 e-messages on ASPs, after which students will be invited to complete a 1-month follow-up assessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-messages for SSB
Description: In the subsequent month after the main intervention, students in the SSB group will receive 4-6 e-messages on SSBs, after which students will be invited to complete a 1-month follow-up assessment.